Purchase this article with an account.
Philip Enders, Paula Scholz, Philipp Muether, Sascha Fauser; Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2666.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze choroidal neovasularization (CNV) activity and recurrence patterns in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab and the correlation with individual intraocular vascular endothelial growth factor (VEGF) suppression time (VST).
Post-hoc analysis of data from a prospective, non-randomized clinical study. Patients with nAMD treated with ranibizumab on a pro re nata regimen. Disease activity was analyzed monthly by spectral-domain optical coherence tomography (SD-OCT) and correlated with VSTs.
73 eyes of 73 patients were included in the study with a mean follow-up of 717 days (range 412-1239 days). Overall, the mean CNV-activity free interval was 76.5 days (range 0 – 829 days). The individual range of the length of dry intervals was high. 42% of patients had a range of more than 90 days. 16% of patients showed persistent activity. 12 % stayed dry after the initial ranibizumab treatment. No significant correlation was found between the CNV recurrence pattern and VST (p = 0.12).
Conclusions: CNV activity in nAMD is irregular which is reflected in the range of the duration of dry intervals and late recurrences. Any OCT-follow up scheme screening for recurrences needs to reflect this high variability.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only